Clinical trial · Observational
A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors
NCT06300216CI-TRIAL-00074833not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this multicenter, open-label, observational study is to evaluate the safety and efficacy of octreotide microspheres in the treatment of advanced neuroendocrine tumors in real clinical practice, especially to evaluate the treatment of octreotide microspheres in various subgroups of neuroendocrine tumor patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroendocrine Tumors | Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Octreotide microspheres | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Octreotide microspheres standard dose monotherapy
- interventionNames
- Drug: Octreotide microspheres
- label
- Octreotide microspheres standard dose combination therapy
- label
- Octreotide microspheres incremental or increased frequency therapy
- label
- Octreotide microspheres maintenance therapy after targeted or chemotherapy
Primary outcomes (1)
- measure
- Treatment Emergent Adverse Events
- timeFrame
- up to 46 months
- description
- Treatment emergent adverse events were recorded according to Common Terminology Criteria for Adverse Events (version 5.0) of the National Cancer Institute that participants received at least one dose of protocol treatment.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Sign an informed consent form and voluntarily participate in this study; 2. Patients with unresectable or metastatic neuroendocrine tumors confirmed by histopathology. Patients with recurrence and progression after surgery or local treatment can also be included in the study; 3. Age ≥ 18 years old; 4. Treatment with octreotide microspheres. Exclusion Criteria: 1. Confirmed pregnant or lactating women; 2. Participating in any research with intervention measures outside of routine clinical practice; 3. Other situations unsuitable for inclusion in the study determined by the researcher.
References
Publications (0)
Data not yet available
No reference posted for this study.